Mereo BioPharma Group plc Stock London S.E.
Equities
MPH
GB00BZ4G2K23
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- GBX | -.--% |
|
-10.17% | -.--% |
Sales 2024 * | 11.39M 14.84M | Sales 2025 * | 12.45M 16.21M | Capitalization | 482M 627M |
---|---|---|---|---|---|
Net income 2024 * | -29M -37.77M | Net income 2025 * | -25M -32.56M | EV / Sales 2024 * | 31.5 x |
Net cash position 2024 * | 123M 160M | Net cash position 2025 * | 118M 154M | EV / Sales 2025 * | 29.2 x |
P/E ratio 2024 * |
-80.4
x | P/E ratio 2025 * |
-112
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.06% |
Managers | Title | Age | Since |
---|---|---|---|
John P. Richard
FOU | Founder | 66 | 15-02-28 |
Founder | 64 | 15-07-09 | |
Charles Sermon
FOU | Founder | 55 | 15-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 19-04-22 |
Marc Yoskowitz
BRD | Director/Board Member | 49 | 22-11-09 |
Director/Board Member | 59 | 19-04-22 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.78% | 126B | |
+24.76% | 118B | |
+24.28% | 27.87B | |
-16.97% | 20.95B | |
-14.83% | 16.92B | |
-13.73% | 16.18B | |
+10.40% | 14.84B | |
-47.10% | 14.79B | |
+53.46% | 14.08B |
- Stock Market
- Equities
- MREO Stock
- MPH Stock